Marilyn C. Pike

1. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
   2022/11/11 by Eric F. Morand, Marilyn C. Pike, Joan T. Merrill +10 · 1 voice · 3 citations
   Medicine · #Systemic Lupus Erythematosus Research #Rheumatoid Arthritis Research and Therapies #Cytokine Signaling Pathways and Interactions